A chance for remission.
A chance for more walks together.
Complete remission is possible after acute lymphoblastic leukemia resists treatment
TECARTUS® is the first and only CAR T-cell therapy for adults with acute lymphoblastic leukemia, or ALL. It may be an option when your cancer resists or returns after your first treatment.
TECARTUS was studied in 54 adults with ALL who had experienced other treatment failures. TECARTUS helped 65% (35 out of 54) of patients achieve overall complete remission. This includes patients who achieved complete remission (28 out of 54) and patients who achieved complete remission with incomplete hematologic recovery (7 out of 54).
TECARTUS uses your own immune system to fight ALL
TECARTUS is different than other cancer medicines because it is made from your own white blood cells, which have been modified to recognize and destroy cancer cells.
Help is available
The Kite Konnect® Support Team is committed to assisting you throughout the treatment journey. For help finding an Authorized Treatment Center, or for information about the support resources that may be available to you once your physician has decided that CAR T-cell therapy is appropriate for you, call Kite Konnect at 1‑844‑454‑KITE , Monday–Friday, 5 AM–6 PM PT.
Please note: Kite Konnect support may be subject to eligibility requirements and other terms and conditions. Contact Kite Konnect for more information.
Authorized Treatment Centers are independent facilities certified to dispense Kite CAR T therapies. Choice of an Authorized Treatment Center is within the sole discretion of the physician and patient. Kite does not endorse any individual treatment sites.
Resources may include referrals to independent third-party nonprofit patient assistance programs. These programs are not operated or controlled by Kite. Nonprofit patient assistance program eligibility requirements may vary and are established solely by each independent organization. Kite makes no guarantee with respect to reimbursement or copay assistance for any item or service.
Cell therapy patient programs are for eligible prescribed patients.